<DOC>
	<DOCNO>NCT00242801</DOCNO>
	<brief_summary>This study carry see add ZD1839 standard supportive care effective standard supportive care alone treatment patient NSCLC whose disease recur previous chemotherapy treatment .</brief_summary>
	<brief_title>Iressa v Best Supportive Care - 2nd/3rd Line Survival Study</brief_title>
	<detailed_description />
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Â· Life expectancy least 8 week . Histologically cytologically confirm nonsmall cell bronchogenic carcinoma : adenocarcinoma ( include bronchoalveolar ) , squamous cell carcinoma , large cell carcinoma mixed ( adenocarcinoma squamous ) undifferentiated carcinoma Not suitable chemotherapy WHO Performance status 0,1 , 2 3 Newly diagnose CNS mets Less 1 week since completion prior radiotherapy persistence radiotherapy relate toxicity ALT/AST great 5 x upper limit normal ANC le 1.0 x 109/L platelet less 100 x 109/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>